{"@context": "https://schema.org", "@graph": [{"@type": "MedicalWebPage", "@id": "https://www.eden.health/learn/fda-peptide-compounding-review-2026", "url": "https://www.eden.health/learn/fda-peptide-compounding-review-2026", "name": "FDA's 2026 peptide review: what the advisory votes and HHS draft policy actually change", "description": "As of November 7, 2026, BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax are not FDA-approved drugs and are not on the list of substances pharmacies may use for compounding. An FDA advisory committee voted in favor of adding six of them in July, and HHS has proposed a draft policy that would let state-licensed pharmacies compound them under conditions. Neither step is final, and Eden does not offer these peptides.", "inLanguage": "en-US", "dateModified": "2026-11-07T12:00:00.000Z", "publisher": {"@type": "Organization", "name": "Eden", "url": "https://www.eden.health/"}, "citation": ["https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026", "https://www.fda.gov/drugs/compounding/compounding-laws-and-policies", "https://www.govinfo.gov/content/pkg/FR-2026-10-30/pdf/2026-22192.pdf", "https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act", "https://www.arnoldporter.com/en/perspectives/advisories/2026/11/hhs-announces-draft-enforcement-discretion-policy-paving-way-for-pharmacies", "https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/"]}, {"@type": "FAQPage", "mainEntity": [{"@type": "Question", "name": "Did the FDA approve BPC-157 or the other peptides?", "acceptedAnswer": {"@type": "Answer", "text": "No. The July 2026 votes were advisory recommendations about compounding, and the HHS policy is a draft. None of the six peptides is an FDA-approved drug."}}, {"@type": "Question", "name": "What is the PCAC?", "acceptedAnswer": {"@type": "Answer", "text": "The Pharmacy Compounding Advisory Committee is a panel of outside experts that advises the FDA on compounding questions, including which bulk substances may be used under section 503A. Its votes do not bind the FDA."}}, {"@type": "Question", "name": "Which peptides did the committee vote against?", "acceptedAnswer": {"@type": "Answer", "text": "Emideltide, also known as DSIP, received a 6–7–1 vote for its proposed uses in opioid withdrawal, chronic insomnia, and narcolepsy. It is not covered by the HHS draft policy."}}, {"@type": "Question", "name": "Can a pharmacy compound these peptides now?", "acceptedAnswer": {"@type": "Answer", "text": "Not under a final rule. The HHS draft policy describes conditions under which the FDA would not take action against 503A pharmacies while rulemaking is pending, but it was still open for comment until November 13, 2026. Ask a licensed pharmacist or prescriber about the current status before relying on it."}}, {"@type": "Question", "name": "Does the policy apply to 503B outsourcing facilities?", "acceptedAnswer": {"@type": "Answer", "text": "No. The draft covers compounding by state-licensed pharmacies, federal facilities, and licensed physicians under section 503A only."}}, {"@type": "Question", "name": "What about GHK-Cu, LL-37, or Melanotan II?", "acceptedAnswer": {"@type": "Answer", "text": "Those are among five peptides the FDA expects to bring to a second advisory committee meeting before the end of February 2027. They are not part of this draft policy."}}, {"@type": "Question", "name": "Does Eden offer these peptides?", "acceptedAnswer": {"@type": "Answer", "text": "No. Eden does not offer, prescribe, compound, or sell BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax, or emideltide. This page is educational only."}}]}, {"@type": "BreadcrumbList", "itemListElement": [{"@type": "ListItem", "position": 1, "name": "Learn", "item": "https://www.eden.health/learn"}, {"@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://www.eden.health/learn-topics/peptides"}, {"@type": "ListItem", "position": 3, "name": "FDA's 2026 peptide review", "item": "https://www.eden.health/learn/fda-peptide-compounding-review-2026"}]}]}
FDA's 2026 peptide review: what the advisory votes and HHS draft policy actually change
As of November 7, 2026, BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax are not FDA-approved drugs and are not on the list of substances pharmacies may use for compounding. An FDA advisory committee voted in favor of adding six of them in July, and HHS has proposed a draft policy that would let state-licensed pharmacies compound them under conditions. Neither step is final, and Eden does not offer these peptides.
An advisory vote is not approval, and a draft policy is not a rule.
The FDA's Pharmacy Compounding Advisory Committee voted on seven peptides in July 2026 and favored adding six to the 503A bulks list; FDA review staff had recommended against them [5]. HHS then issued a draft enforcement-discretion policy for those six, open for comment until November 13, 2026. It does not approve any peptide or add it to the list [3].
Get AI summary
Where things stand
The six peptides at a glance
These are the facts we could verify against FDA and Federal Register records as of November 7, 2026.
The committee backed six of seven peptides, mostly by narrow margins
The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which bulk substances state-licensed pharmacies may use under section 503A. Each vote below was tied to a specific use the nominator proposed. A favorable vote is a recommendation to the FDA, not a decision. [1]
Peptide
Use reviewed
Vote (yes–no–abstain)
Committee view
BPC-157
Ulcerative colitis
8–6–1
In favor
KPV
Wound healing and inflammatory conditions
8–6–1
In favor
TB-500
Wound healing
8–6–1
In favor
MOTS-c
Obesity and osteoporosis
7–5–2
In favor
Epitalon
Insomnia
7–4–1
In favor
Semax
Cerebral ischemia, migraine, trigeminal neuralgia
8–5–1
In favor
Emideltide (DSIP)
Opioid withdrawal, chronic insomnia, narcolepsy
6–7–1
Against
Vote counts as reported in a public summary of the meeting [6]. Check the FDA meeting materials [1] for the official record.
HHS draft policy
HHS proposed letting 503A pharmacies compound the six peptides under strict conditions
HHS announced the draft policy on October 28, 2026, and published it in the Federal Register on October 30. It describes when the FDA would not take action against compounding while each peptide waits for a final rule. It is a draft: it does not bind the FDA and creates no rights. [3]
A pharmacy relying on the policy would have to, among other conditions:
Fill a valid prescription for an identified patient
Use a single listed peptide, from an FDA-registered manufacturer, with a valid certificate of analysis
Confirm the original manufacturer follows current good manufacturing practice, not just a distributor
Report serious adverse events and quality problems to FDA MedWatch and to the state
Label the product “This is a compounded drug product. Not for resale.” [3]
What the draft policy does
Signals that the FDA would not act against qualifying 503A compounding of the six peptides while rulemaking is pending [3]
Sets sourcing, labeling, and reporting conditions that compounders must meet
Lasts only until each peptide is added to, or excluded from, the bulks list by a final rule [5]
What it does not do
None of these steps turns a peptide into an approved medicine.
Approve any peptide as safe or effective for any use
Add any peptide to the 503A bulks list
Cover 503B outsourcing facilities
Cover products sold online as “research use only,” which are not compounded under a patient-specific prescription
Take effect in final form before the comment period closes and HHS responds
What comes next
More steps, and more peptides, are still ahead
For any of the six peptides to be permanently allowed in 503A compounding, the FDA would need to publish a proposed rule, take public comment, and issue a final rule adding it to the bulks list. We found no proposed rule as of November 7, 2026. [4]
The FDA has also said a second advisory committee meeting, expected before the end of February 2027, will review GHK-Cu, Dihexa acetate, cathelicidin (LL-37), PEG-MGF, and Melanotan II. Those five remain outside this draft policy. [4]
Safety and access
Regulatory progress is not evidence that these peptides work or are safe
The committee voted on whether pharmacies may compound these substances, not on whether they are proven treatments. Compounded drugs are not FDA-approved, which means the FDA does not review them for safety, effectiveness, or quality before they are dispensed. [2]
FDA approval
None
None of the six peptides is an FDA-approved drug, and the draft policy does not change that. [3]
Compounded access
Draft, 503A only
If the policy is finalized, access would run through a licensed prescriber and a state-licensed 503A pharmacy that meets every condition. [3]
“Research use only” products
Outside the policy
Peptides sold online for research use are not made for patients and fall outside the draft policy's conditions. [3]
Common questions
Direct answers
Each answer starts with the conclusion, then gives the limitation or source context you need.
Did the FDA approve BPC-157 or the other peptides?
No. The July 2026 votes were advisory recommendations about compounding, and the HHS policy is a draft. None of the six peptides is an FDA-approved drug. [3]
What is the PCAC?
The Pharmacy Compounding Advisory Committee is a panel of outside experts that advises the FDA on compounding questions, including which bulk substances may be used under section 503A. Its votes do not bind the FDA. [1]
Which peptides did the committee vote against?
Emideltide, also known as DSIP, received a 6–7–1 vote for its proposed uses in opioid withdrawal, chronic insomnia, and narcolepsy. It is not covered by the HHS draft policy. [6]
Can a pharmacy compound these peptides now?
Not under a final rule. The HHS draft policy describes conditions under which the FDA would not take action against 503A pharmacies while rulemaking is pending, but it was still open for comment until November 13, 2026. Ask a licensed pharmacist or prescriber about the current status before relying on it. [3]
Does the policy apply to 503B outsourcing facilities?
No. The draft covers compounding by state-licensed pharmacies, federal facilities, and licensed physicians under section 503A only. [3]
What about GHK-Cu, LL-37, or Melanotan II?
Those are among five peptides the FDA expects to bring to a second advisory committee meeting before the end of February 2027. They are not part of this draft policy. [4]
Does Eden offer these peptides?
No. Eden does not offer, prescribe, compound, or sell BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax, or emideltide. This page is educational only.
Source transparency
Primary sources behind this page
Material statements are tied to regulators, peer-reviewed research, registered trials, or the developer's current status disclosures. Affiliate summaries are never used as clinical or regulatory proof.
Educational information only. This page is not medical or legal advice and does not replace evaluation by a licensed healthcare professional. Eden does not offer the peptides discussed here.
Explore treatment options with Eden
See which treatments are available, how they work, and what they cost. If one looks right for you, a licensed clinician reviews your online intake.
